We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA) (SEROLA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00885690
Recruitment Status : Terminated (Due to recruitment problems)
First Posted : April 22, 2009
Last Update Posted : September 4, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
Cognition is one of the core symptoms of schizophrenia. This study is a head-to-head trial between olanzapine and sertindole with cognition as primary outcome. The design is a 12-week double-blinded randomized controlled flexible dose study.

Condition or disease Intervention/treatment
Schizophrenia Drug: Sertindole Drug: Olanzapine

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicentre Double-blinded Randomized Head-to-head Study
Study Start Date : April 2009
Primary Completion Date : November 2012
Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Sertindole
Sertindole 16-24 mg
Drug: Sertindole
Sertindole 16-24 mg once daily
Other Name: Serdolect
Active Comparator: Olanzapine
Olanzapine 10-20 mg
Drug: Olanzapine
Olanzapine 10-20 mg
Other Name: Zyprexa

Outcome Measures

Primary Outcome Measures :
  1. CANTAB cognitive test battery [ Time Frame: Baseline - 6 and 12 weeks ]

Secondary Outcome Measures :
  1. Fasting glucose, lipid profile, HbA1c, body weight, abdominal circumference, blood pressure [ Time Frame: Baseline - 6 and 12 weeks ]
  2. PANSS, CGI, Sf-36 (quality of life), GAF (social function), UKU (side effects), DAI (attitude towards medicine), Beck's insight scale, Specific Level of Functioning (SLOF) [ Time Frame: Baseline, 6 and 12 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • AnICD-10 schizophrenia diagnosis F20.0-F20.9.
  • Contraception.
  • A negative pregnancy test for women.
  • No known allergy to any of the substances in the study medication
  • Baseline QTc < 450 milliseconds for men and < 470 milliseconds for women
  • S-potassium and s-magnesium within normal reference range.
  • Suboptimally treated on current antipsychotic medication
  • Stable dosage of antidepressants and mood stabilizers one month before the inclusion
  • Signed informed consent and power of attorney

Exclusion Criteria:

  • Withdrawal of consent
  • QTc prolongation >500 milliseconds during the study
  • Patients with known clinical important cardiovascular disease
  • Significant substance abuse
  • Earlier partial or non-response in treatment or intolerability to sertindole or olanzapine.
  • Calgary Depression Scale score ≥ 7
  • Treatment that interferes with the metabolism of sertindole or olanzapine,
  • Oxazepam, zopiclone or zolpidem treatment the last 48 hours before cognitive testing
  • Prescription of not-allowed medication, or a change in dosage of antidepressant, or mood stabilizers in the study period
  • Treatment with an anticholinergic after the first three weeks of the study
  • Somatic illness, as judged by investigator, interfering with cognition
  • Known risk of narrow angle glaucoma
  • Treatment with electroconvulsive therapy (ECT) the last three months before inclusion, or treatment with ECT in the study period
  • Treatment with clozapine or depot antipsychotics before inclusion
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00885690

Aalborg Psychiatric Hospital
Aalborg, Denmark, 9000
Universitets Allmänna Sjukhuset, Malmø UMAS
Malmø, Sweden
Sponsors and Collaborators
University of Aarhus
Aalborg Psychiatric Hospital
Malmö University
Principal Investigator: René Nielsen, M.D. Aalborg Psychiatric Hospital, Aarhus University Hospital
More Information

Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT00885690     History of Changes
Other Study ID Numbers: 3.1 - 01-25-09
Eudra CT nr: 2008-008366-13
First Posted: April 22, 2009    Key Record Dates
Last Update Posted: September 4, 2013
Last Verified: September 2013

Keywords provided by University of Aarhus:

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents